| 1. |
|
|
| 2. |
- Lindberg, Anne, et al.
(författare)
-
Decline in FEV1 in relation to incident chronic obstructive pulmonary disease in a cohort with respiratory symptoms.
- 2007
-
Ingår i: COPD. - : Informa UK Limited. - 1541-2555. ; 4:1, s. 5-13
-
Tidskriftsartikel (refereegranskat)abstract
- Data on the relationship between decline in lung function and development of COPD are sparse. We assessed the decline in FEV1 during 10 years among subjects with respiratory symptoms by two different methods and evaluated risk factors for decline and its relation to incident Chronic Obstructive Pulmonary Disease, COPD. A cross-sectional postal questionnaire was in 1986 sent to 6610 subjects of three age strata. All subjects reporting respiratory symptoms were invited to a structured interview and spirometry. A follow-up survey was performed 10 years later, and totally 1109 subjects performed spirometry in both 1986 and 1996. COPD was defined according to the ATS/ERS standards (FEV1/FVC < or =0.70). The decline in FEV1 was 39 ml/year in men vs. 28 ml/year in women, p = < 0.001 (-1.53 vs. -0.12 change in percent of predicted normal value over 10 years (pp), p = 0.023), among smokers 39 vs. non-smokers 28 ml/year, p < 0.001 (-3.30 vs. 0.69 pp, p < 0.001), in subjects with chronic productive cough 36 vs. not 32 ml/year, p = 0.044 (-2.00 vs. -0.02 pp, p = 0.002). Incident cases of moderate COPD (n = 83) had a decline of 62 ml/year (-12.6 pp) and 22.9% of them had a decline > 90 ml/year (-27.8 pp over 10 years). Gender-specific analysis revealed that smoking was a stronger risk factor in women than in men, while higher age was a significant risk factor in men only. In conclusion, decline in FEV1 was associated with age, smoking, and chronic productive cough, but the risk factor pattern was gender-dependent. Among incident cases of COPD the decline was steeper and close to a quarter had a rapid decline.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
- Cetinkaya, Cihan, et al.
(författare)
-
Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells
- 2007
-
Ingår i: Molecular Cancer Therapeutics. - 1535-7163 .- 1538-8514. ; 6:10, s. 2634-2641
-
Tidskriftsartikel (refereegranskat)abstract
- The MYCN protooncogene is involved in the control of cell proliferation, differentiation, and survival of neuroblasts. Deregulation of MYCN by gene amplification contributes to neuroblastoma development and is strongly correlated to advanced disease and poor outcome, emphasizing the urge for new therapeutic strategies targeting MYCN function. The transcription factor N-Myc, encoded by MYCN, regulates numerous genes together with its partner Max, which also functions as a cofactor for the Mad/Mnt family of Myc antagonists/transcriptional repressors. We and others have previously reported that IFN-gamma synergistically potentiates retinoic acid (RA)induced sympathetic differentiation and growth inhibition in neuroblastoma cells. This study shows that combined treatment of MYCN-amplified neuroblastorna cells with RA+IFN-gamma down-regulates N-Myc protein expression through increased protein turnover, up-regulates Mad1 mRNA and protein, and reduces N-Myc/Max heteroclimerization. This results in a shift of occupancy at the ornithine decarboxylase N-Myc/Mad1 target promoter in vivo from N-Myc/Max to Madl/Max predominance, correlating with histone H4 deacetylation, indicative of a chromatin structure typical of a transcriptionally repressed state. This is further supported by data showing that RA + IFN-gamma treatment strongly represses expression of N-Myc/Mad1 target genes ornithine decarboxylase and hTERT. Our results suggest that combined IFN-gamma and RA signaling can form a basis for new therapeutic strategies targeting N-Myc function for patients with high-risk, MYCN-amplified neuroblastoma.
|
|
| 7. |
- Ejhed, Helene, et al.
(författare)
-
Miljömålsuppföljning Ingen övergödning 1995 och 2005 : Slutrapport
- 2007
-
Rapport (övrigt vetenskapligt/konstnärligt)abstract
- En uppföljning av två delmål för miljökvalitetsmålet Ingen övergödning mellan år 1995 och 2005 har genomförts av SMED på uppdrag av Naturvårdsverket. Det gäller specifikt delmålen om tillförseln av kväve och fosfor till havet respektive till vatten. Underlag och indata till beräkningarna har tagits fram inom det parallella PLC5- projektet som genomförs för rapportering till HELCOM och från TRK-projektet (Brandt och Ejhed 2002). Metodik för beräkningarna har utvecklats mycket sedan TRK-projektet och beskrivs utförligt i rapporten. En av de största förändringarna i metodik har genomförts för fosfor belastningsberäkningar från jordbruksmark där nya mer fysikaliska modeller använts. Ytterligare en stor förändring har varit användning av Tekniskt Beräkningssystem Vatten (TBV) som ska medföra en mer kvalitetssäkrad hantering av beräkningarnaResultaten i denna rapport presenteras och bedöms med avseende på kvalitet och jämförs med transporterade mängder i flodmynningarna, TRK-resultat och resultat i HBV-NP.Resultaten visar att den antropogena belastningen av kväve minskat med cirka 25 % från år 1995 till år 2005 för de svenska vattenburna utsläppen till haven söder om Ålands hav. Delmålet för kväve anger en minskning med 30 % till år 2010.Resultaten visar vidare att den antropogena bruttobelastningen av fosfor minskat med cirka 14 % från år 1995 till år 2005 för de svenska vattenburna utsläppen till sjöar, vattendrag och kustvatten. Delmålet för fosfor anger en minskning med minst 20 procent till år 2010
|
|
| 8. |
- Froitzheim, Jan, 1981, et al.
(författare)
-
Chromium evaporation of Coated and uncoated FE-22CR steels investigated by a novel denuder technique
- 2009
-
Ingår i: 3rd European Fuel Cell Technology and Applications - Piero Lunghi Conference, EFC 2009; Rome; Italy; 15 December 2009 through 18 December 2009. - 9788882862114 ; , s. 77-78
-
Konferensbidrag (refereegranskat)abstract
- The formation of volatile chromium species is a major problem concerning metallic interconnects for Solid Oxide Fuel Cells (SOFC). This problem is known and a number of routes, usually in the form of coatings, has been presented to overcome this problem. This paper investigates the influence of thin metallic films which can be applied by a low cost process. The measurements are carried out by a novel denuder technique where volatile chromium species are collected as sodium chromate. This technique allows the quantification of chromium evaporation in a time resolved manner. Coated and uncoated samples of ferritic steels developed for SOFC applications are investigated at 850°C in a N2-O2-H2O environment.
|
|
| 9. |
- Froitzheim, Jan, 1981, et al.
(författare)
-
Cr evaporation of metallic interconnects: A novel method for quantification
- 2009
-
Ingår i: ECS Transactions. - : The Electrochemical Society. - 1938-5862 .- 1938-6737. - 9781566777391 ; 25:2 PART 2, s. 1423-1428
-
Konferensbidrag (refereegranskat)abstract
- Chromium evaporation from metallic interconnects in SOFCs is commonly poisoning the cathode of SOFCs. To reduce chromium evaporation, rather thick coatings have been deposited using various coating techniques. In this study, a 22% Cr ferritic steel has been coated with thin films (
|
|
| 10. |
- Gudjonsson, Sigurdur, et al.
(författare)
-
Should All Patients with Non-Muscle-Invasive Bladder Cancer Receive Early Intravesical Chemotherapy after Transurethral Resection? The Results of a Prospective Randomised Multicentre Study.
- 2009
-
Ingår i: European Urology. - : Elsevier BV. - 1873-7560 .- 0302-2838. ; 55, s. 773-780
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: To decrease recurrences in non-muscle-invasive bladder cancer (NMIBC), the European Association of Urology (EAU) guidelines recommend immediate, intravesical chemotherapy after transurethral resection (TUR) for all patients with Ta/T1 tumours. OBJECTIVE: To study the benefits of a single, early, intravesical instillation of epirubicin after TUR in patients with low- to intermediate-risk NMIBC. DESIGN, SETTING, AND PARTICIPANTS: In this prospective randomised multicentre trial, 305 patients with primary as well as recurrent low- to intermediate-risk (Ta/T1, G1/G2) tumours were enrolled between 1997 and 2004. Patients were randomly allocated to receive 80mg of epirubicin in 50ml of saline intravesically within 24h of TUR or no further treatment after TUR. MEASUREMENTS: The primary end point was time to first recurrence. RESULTS AND LIMITATIONS: A total of 219 patients remained for analysis after exclusions. The median follow-up time was 3.9 yr. During the study period, 62% (63 of 102) of the patients in the epirubicin group and 77% (90 of 117) in the control group experienced recurrence (p=0.016). In a multivariate model, the hazard ratio (HR) for recurrence was 0.56 (p=0.002) for early instillation of epirubicin versus no treatment. In a subgroup analysis, the treatment had a profound recurrence-reducing effect on patients with primary, solitary tumours, whereas it provided no benefits in patients with recurrent or multiple tumours. Furthermore, patients with a modified European Organisation for Research and Treatment of Cancer (EORTC) risk score of 0-2 with and without single instillation had recurrence rates of 41% and 69%, respectively (p=0.003), whereas the corresponding rates for those with a risk score of >/=3 were 81% and 85%, respectively (p=0.35). CONCLUSIONS: A single, early instillation of epirubicin after TUR for NMIBC reduces the likelihood of tumour recurrence; however, the benefit seems to be minimal in patients at intermediate or high risk of recurrence. Future trials will determine the value of early instillation in addition to serial instillations in NMIBC.
|
|
